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Conclusions. Measurement of patient setup using trachea contour is possible. We have identiﬁed the position of the trachea at
DRR as a surrogate marker during 3D radiotherapy and it is possible to reduce the interobserver variability for verifying patient
initial and the daily variation setup in lung cancer patients
http://dx.doi.org/10.1016/j.rpor.2013.03.298
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Introduction and objective. In the evaluation of the toxicity in the treatment of lung carcinoma parameters such as V13, V20, V30
and mean dose (MLD) are used (Biau et al., Pro 2012). Planning target volume (PTV) is usually subtracted from the lung volume
although some studies subtract gross tumor volume (GTV). The aim of this study is to analyze the differences between the use
of lung-PTV or lung-GTV in pulmonary toxicity evaluation. Relations between the parameters V13, V20, V30, and MLD using the
volumes lung-PTV and lung-GTV are studied, as well as the possible relationship between these parameters and the volumes of
GTV, PTV and lung volume.
Material and methods. From 09/2010 to 12/2012, 65 p NSCLC were treated with 3D-RT radical intent. Sex: 52 p (80%) male/13 p (20%)
women, mean age 60years (33–82). Histological type: 29 p (44.6%) adenocarcinoma/27 p (41.5%) squamous cell carcinoma/9 p
(13.8%) other histologies. Stage distribution: 13 p (20%) IIIA/52 p (80%) IIIB. Primary tumor: 32 p (49.2%) upper-lobe/17 p (26.2%)
hilum/12 p (18.5%) lower-lobe/4 p (6.2%) middle-lobe. QT concurrent: 84%p. GTV-medium: 149.66 cm3 (7–617) and PTV-medium:
532 cm3 (0–1119). 100%p outlined lung-GTV/lung-PTV and calculated V13, V20, V30 and MLD at each planning.
Results. We found signiﬁcant differences between the parameters V13, V20, V30 of the volumes lung-PTV and lung-GTV, with
mean differences of 3.5%, 4.0% and 4.3% higher for the V13, V20 and V30 lung-GTV than for lung-PTV. Mean difference in
volume between lung and lung-PTV-GTV is 170 cm3 (21–334 cm3). The reduction in lung-MLD regarding lung PTV-GTV is 2.27Gy
(0.25–4.88Gy). There is a strong correlation between the parameters V13, V20, V30 and mean dose. No relationship was found
between total dose and V13, V20 and V30 neither between the volumes of GTV or PTV and V13, V20 and V30.
Conclusions. In the analysis of the relationship between the different dosimetric parameters to evaluate pulmonary toxicity we
have found a strong correlation between V13, V20, V30 and MLD. Use of lung-PTV or lung-GTV for the evaluation of these
parameters presents signiﬁcant differences and thus it should be considered in the treatment plan evaluation.
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Introduction. Stereotactic ablative radiotherapy (SABR) has emerged as a standard treatment option for stage I non-small cell lung
cancer (NSCLC) in patients unﬁt for surgery, or who refuse surgery. An increasing number of prospective phase I/II trials, as well
as large single and multicenter studies have reported local control rates to be in excess of 85% for early stage NSCLC.
Purpose/objective. Volumetric arc therapy (VMAT) RapidArc® with tumor-based image guidance technique will be presented as
well as our preliminary observations.
Material and methods. Five selected patients (T1-2N0 NSCLC) were treated with SABR. No external rigid immobilization was used
(only arm and knee support). Planning images were acquired with a free breathing slow CT and transferred to Varian Eclipse
Treatment Planning System (TPS) for VMAT optimization and dose calculation. Planning objectives were set in accordance to
RTOG and AAPM protocols. SABR was delivered using online cone-beam CT guidance to a total dose of 60Gy, in 3, 5 or 8 fractions,
depending on tumor size and location. Dose was prescribed to 80% isodose, where possible covering 95% of PTV.
Results. CBCT-guidance using soft-tissue matching on the tumor itself, rather than the bony anatomy of the patient, is essential
because lung patients can have large set-up errors due to changes in anatomy between CT and treatment, weight loss, body
rotations and arm positioning variability. In addition to excellent plan quality, RapidArc® SABR has the beneﬁt of fast delivery
improving the patient comfort and minimizing intrafraction motion. The SABR treatment was well tolerated with minimal acute
side effects. Post-SABR lung acute patterns were observed on CT follow-up.
Conclusions/Discussion. RapidArc® VMAT allows for fast delivery of stereotactic ablative radiotherapy delivery in lung cancer
treatment, requiring CBCT image guidance for accurate patient set-up and tumor position.
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